Ephrin type-A receptor 2 (EphA2) overexpression has been correlated with a poor prognosis in most cancer types, including endometrial (1), colorectal (2), breast (3), ovarian (4), and Glioblastoma multiforme (GBM) (5, 6). Here, EPHA2 is linked to glioblastoma.